Cassava Sciences- Warrants (15/11/2024) Return on Equity

Cassava Sciences- Warrants (15/11/2024) (SAVAW) currently reports a ROE of -66.47%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Cassava Sciences- Warrants (15/11/2024)'s ROE history and peer comparisons.

Cassava Sciences- Warrants (15/11/2024)'s ROE of -66.47% is lower than the Healthcare sector average of 21.67%. That is roughly 406.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cassava Sciences- Warrants (15/11/2024)'s current -66.47% should be judged against Healthcare norms (sector average: 21.67%) and against SAVAW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -66.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Cassava Sciences- Warrants (15/11/2024), and consider following SAVAW for alerts when major investors trade the stock.

Cassava Sciences- Warrants (15/11/2024) is classified in the Healthcare sector. On ROE, it currently shows -66.47% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SAVAW with unrelated industries.